Tandem Diabetes Care Inc. (TNDM)

NASDAQ: TNDM · Real-Time Price · USD

20.21

3.36 (19.94%)

At close: May 01, 2025, 3:40 PM

19.94% (1D)

Bid	20.08
Market Cap	1.35B
Revenue (ttm)	1.06B
Net Income (ttm)	-96.03M
EPS (ttm)	-1.47
PE Ratio (ttm)	-13.75
Forward PE	-25.55
Analyst	Buy

Ask	20.28
Volume	3,803,837
Avg. Volume (20D)	1,729,934
Open	18.66
Previous Close	16.85
Day's Range	18.27 - 20.39
52-Week Range	15.75 - 53.69
Beta	1.53

About TNDM

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technolo...

[Read more]

Industry Medical - Devices

Sector Healthcare

IPO Date Nov 14, 2013

Employees 2,650

Stock Exchange NASDAQ

Ticker Symbol TNDM

Website https://www.tandemdiabetes.com

Full Company Profile

Analyst Forecast

According to 15 analyst ratings, the average rating for TNDM stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 53.39% from the latest price.

Stock Forecasts

Earnings Surprise

New

Tandem Diabetes Care has released their quartely earnings on Apr 30, 2025:

Revenue of $234.42M exceeds estimates by $14.2M, with 22.30% YoY growth.

EPS of -0.665 misses estimates by -0.06, with -3.91% YoY decline.

Why Price Moved

5 hours ago New

Tandem Diabetes shares are trading higher after th... Unlock content with Pro Subscription

2 weeks ago

-2.32%

Shares of diabetes stocks are trading lower following successful obesity data from Lilly.

News

23 hours ago · seekingalpha.com

Tandem Diabetes Care, Inc. (TNDM) Q1 2025 Earnings Conference Call Transcript

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Susan Morrison - EVP & Chief Administrative Officer John Sheridan - President ...

23 hours ago · zacks.com

Tandem Diabetes Care (TNDM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with...

1 day ago · zacks.com

Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.63 per share a year ago.

1 day ago · zacks.com

What to Expect From These 3 MedTech Stocks This Earnings Season?

Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow.

1 week ago · zacks.com

Reasons to Hold TNDM Stock in Your Portfolio for Now

A robust diabetes market and international expansion raise investors' optimism for Tandem Diabetes.

2 weeks ago · zacks.com

Tap Into the Silver Economy Boom With These Aging Demographics Stocks

The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.

2 weeks ago · fool.com

2 Beaten-Down Stocks to Avoid in the Tariff-Fueled Correction

With equity markets reeling due to President Donald Trump's tariffs, many investors are taking this opportunity to buy shares of top companies on the dip. It's a great strategy, but it's essential to ...

2 weeks ago · zacks.com

Tandem Diabetes Care (TNDM) Moves 7.6% Higher: Will This Strength Last?

Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n...

4 weeks ago · businesswire.com

Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2025 results after the financial m...

1 month ago · zacks.com

TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology

Tandem Diabetes launches Control-IQ+ technology commercially in the United States. Control-IQ+ is compatible with t:slim X2 insulin pump and Tandem Mobi System.

Load More News